Nektar Therapeutics buy Midas
Start price
04.12.20
/
50%
€14.29
Target price
04.12.21
-
Performance (%)
47.17%
End price
20.02.21
€21.03
Summary
This prediction ended on 20.02.21 with a price of €21.03. With a performance of 47.17% the BUY prediction by Midas was a big success. Midas has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nektar Therapeutics | 5.328% | 5.328% | 97.281% | -91.771% |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
Comments by Midas for this prediction
In the thread Discuss Nektar Therapeutics
Buy Nektar Therapeutics